Thrombocytopenia in liver disease

From HemOnc.org - A Hematology Oncology Wiki
Revision as of 16:36, 22 May 2018 by Benjamintillman (talk | contribs) (Created page with "== Thrombocytopenia in liver disease with planned procedure == <big>Avatrombopag (Doptelet)</big> {| class="wikitable" |- ! Study !! Evidence !! Comparator !! Efficacy |- |...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Thrombocytopenia in liver disease with planned procedure

Avatrombopag (Doptelet)

Study Evidence Comparator Efficacy
ADAPT-1 Phase III Placebo Superior RR
ADAPT-2 Phase III Placebo Superior RR

Avatrombopag

  • High dose 60 mg/d PO on days 1 to 5 (Patients with platelet count < 40 x 109/L)
  • Low dose 40 mg/d PO on days 1 to 5 (Patients with platelet count 40 x 109/L - < 50 x 109/L)

Procedure days were days 10 to 13.

Retrieved from "https://hemonc.org/w/index.php?title=Thrombocytopenia_in_liver_disease&oldid=26998"